The use of cannabinoids in the treatment of mental and behavioral disorders
Suggested citation:
Klimenko TV, Korchagina GA, Igumnov SA. [The use of cannabinoids in the treatment of mental and behavioral disorders]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2021;(2):62-72. Russian
In this scientific review, in order to study the current state of the issue of the use of cannabinoids for medical purposes, an analysis of available foreign systematic reviews and randomized controlled trials on the effectiveness and safety of cannabis-based drugs in patients with various, including mental disorders, was conducted. It is shown that the data accumulated to date on the effectiveness of the use of cannabis and its metabolites in medical practice are contradictory, do not give a clear opinion on its therapeutic effectiveness, which requires further study of the therapeutic potential of cannabinoids with an assessment of long-term effects in as many patients as possible.
Keywords cannabis; cannabinoid receptors; mental disorders; treatment; therapeutic efficacy
1. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007;4(8):1729–43. DOI: https://doi.org/10.1002/cbdv.200790150 2. IOM (Institute of Medicine). Marijuana and medicine: Assessing the science base. Washington, DC: National Academy Press; 1999. 288 p. DOI: https://doi.org/10.17226/6376 3. Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int. 2012;109(29–30):495–501. DOI: https://doi.org/10.3238/arztebl.2012.0495 4. NCSL (National Conference of State Legislatures). State medical marijuana laws. URL: http:// www.ncsl.org/research/health/state-medical-marijuana-laws.aspx (accessed on: 24.03.2021). 5. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: Pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 20212;367(1607):3353–63. DOI: https://doi.org/10.1098/rstb.2011.0381 6. Schauer GL, King BA, Bunnell RE, et al. Toking, vaping, and eating for health or fun: Marijuana use patterns in adults, U.S., 2014. Am J Prev Med. 2016;50(1):1–8. DOI: https://doi.org/10.1016/j.amepre.2015.05.027 7. GW Pharmaceuticals. Prescriber information. November 15, 2016. URL: http://dev-gwpharma.pantheonsite.io/products-pipeline/sativex/prescriber-information-full (accessed on: 24.03.2021). 8. Belendiuk KA, Baldini LL, Bonn-Miller MO. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:10. DOI: https://doi.org/10.1186/s13722-015-0032-7 9. Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: A randomized clinical trial. JAMA Psychiatry. 2014;71(3):281–91. DOI: https://doi.org/10.1001/jamapsychiatry.2013.3947 10. Romancova TI. Jendokannabinoidnaja sistema: struktura i potencial'nye vozmozhnosti v reguljacii massy tela. Ozhirenie i metabolizm. 2006;(2):2–11. (In Russ.) 11. Ovsjannikov VG, et al. Antinociceptivnaja Sistema. Medicinskij vestnik Juga Rossii. 2014;(3):46–54. (In Russ.) DOI: https://doi.org/10.21886/2219-8075-2014-3-46-54 12. APA (American Psychiatric Association). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing; 2013. 991 p. 13. Nezhuta AJu, Melik-Kasumov TB, Ivanova EV. Vlijanie ligandov kannabinoidnyh receptorov na latentnyj period bolevogo refleksa i afferentnuju impul'saciju v podkozhnom nerve bedra zdorovyh krys. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta. 2009;2(26):46–8. (In Russ.) 14. Churjukanov VV, Hodorovich NA, Shevelev OA. Agonisty kannabinoidnyh receptorov usilivajut kortikal'nyj kontrol' nociceptivnyh signalov v jadrah trojnichnogo nerva. Bolevye sindromy v medicinskoj praktike: Materialy XVII Ros. nauch.-prakt. konf. s mezhdunar. Uchastiem. Rossijskij zhurnal boli. 2011;(2):20. (In Russ.) 15. Krylatov AV. Kannabinoidergicheskaja reguljacija funkcional'nogo sostojanija serdca. Rol' vegetativnoj nervnoj sistemy. Rossijskij fiziologicheskij zhurnal im. IM Sechenova. 2017;103(7):727–43. (In Russ.) 16. Tromza VE, Nikiforova IN. Anal'geticheskie svojstva kannabinoidnyh ligandov WIN 55,212–2 i AM 1241 v testah otdergivanija hvosta i gorjachej plastiny. Rossijskij zhurnal boli. 2010;1(26):8–11. (In Russ.) 17. Molchanova AJu, Ulashhik VS. Kannabinoidy i molekuljarno-biologicheskie mehanizmy kancerogeneza. Zdravoohranenie (Minsk). 2015;(2):32–40. (In Russ.) 18. NIH (National Institutes of Health). The dementias: Hope through research. NIH Publication No. 17-NS-2252. December 2017. URL: https://order.nia.nih.gov/sites/default/files/2018-01/the-dementias-hope-through-research.pdf (accessed on: 24.03.2021). 19. NIA (National Institute on Aging). n.d. About Alzheimer's disease: Other dementias. URL: https://www.nia.nih.gov/alzheimers/topics/other-dementias (accessed оn: 24.03.2021). 20. Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev. 2009;(2):CD007204. DOI: https://doi.org/10.1002/14651858.CD007204.pub2 21. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol. 2003;2(5):291–8. DOI: https://doi.org/10.1016/s1474-4422(03)00381-8 22. Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs. 2002;11(10):1365–74. DOI: https://doi.org/10.1517/13543784.11.10.1365 23. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and delta- 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998;95(14):8268–73. DOI: https://doi.org/10.1073/pnas.95.14.8268 24. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hip-pocampal neurons from excitotoxicity. Mol Pharmacol. 1998;54(3):459–62. DOI: https://doi.org/10.1124/mol.54.3.459 25. Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12(9):913–9. PMID: 9309469 26. van den Elsen GAH, Ahmed AIA, Verkes RJ, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology. 2015;84(23):2338–46. DOI: https://doi.org/10.1212/WNL.0000000000001675 27. Gardner EL. Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacol Biochem Behav. 2005;81(2):263–84. DOI: https://doi.org/10.1016/j.pbb.2005.01.032 28. Heifets BD, Castillo PE. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol. 2009;71:283–306. DOI: https://doi.org/10.1146/annurev.physiol.010908.163149 29. Budney AJ, Vandrey RG, Hughes JR, et al. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86(1):22–9. DOI: https://doi.org/10.1016/j.drugalcdep.2006.04.014 30. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29(1):158–70. DOI: https://doi.org/10.1038/sj.npp.1300310 31. Levin FR, Mariani JJ, Brooks DJ, et al. Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116(1–3):142–50. DOI: https://doi.org/10.1016/j.drugalcdep.2010.12.010 32. Marshall K, Gowing L, Ali R, Le Foll B. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2014;12(12):CD008940. DOI: https://doi.org/10.1002/14651858.CD008940.pub2 33. Morgan CJA, Das RK, Joye A, et al. Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings. Addict Behav. 2013;38(9):2433–6. DOI: https://doi.org/10.1016/j.addbeh.2013.03.011 34. NIMH (National Institute of Mental Health). Schizophrenia. 2015. URL: https://www.nimh.nih.gov/health/publications/schizophrenia-booklet-12-2015/index.shtml (accessed on: 24.03.2021). 35. McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014;(10):CD004837. DOI: https://doi.org/10.1002/14651858.CD004837.pub3 36. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313(24):2456247. DOI: https://doi.org/10.1001/jama.2015.6358 37. ADAA (Anxiety and Depression Association of America). Depression. 2016. URL: https://www.adaa.org/understanding-anxiety/depression (accessed on: 24.03.2021). 38. NIDA (National Institute on Drug Abuse). Research reports: Marijuana. 2015. URL: https://www.drugabuse.gov/sites/default/files/mjrrs_4_15.pdf (accessed on: 24.03.2021). 39. Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585–8. DOI: https://doi.org/10.1016/j.psyneuen.2014.11.002 40. Sateia MJ. International classification of sleep disorders, third edition: Highlights and modifications. Chest. 2014;146(5):1387–94. DOI: https://doi.org/10.1378/chest.14-0970 41. Garcia AN, Salloum IM. Polysomnograhic sleep disturbances in nicotine, cafeine, alcohol, cocaine, opioid, and cannabis use: A focused review. Am J Addict. 2015;24(7):590–8. DOI: https://doi.org/10.1111/ajad.12291 42. Andries A, Frystyk J, Flyvbjerg A, Støving RK. Dronabinol in severe, persistent anorexia nervosa: a randomized controlled trial. Int J Eat Disord. 2014;47:18–23. 43. Cyr C, Arboleda MF, Aggarwal SK, et al. Cannabis in palliative care: current challenges and practical recommendations. Ann Palliat Med. 2018;7(4):463–77. DOI: https://doi.org/10.21037/apm.2018.06.04 44. Allan GM, Finley CR, Ton J, et al. Systematic review of systematic reviews for medical cannabinoids. Pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64(2):e78–e94. PMID: 29449262 45. Rasche T, Emmert D, Stieber C, et al. Cannabis und Cannabinoide – erleichterter Zugang, Hype und Enttäuschung: Was ist gesichert in der Therapie? [Cannabis and cannabinoids-easier access, hype and disappointment: What has been confirmed in therapy?]. Internist (Berl). 2019;60(3):309–14. (In German) DOI: https://doi.org/10.1007/s00108-019-0556-0 46. Briscoe J, Kamal AH, Casarett DJ. Top Ten Tips Palliative Care Clinicians Should Know About Medical Cannabis. J Palliat Med. 2019;22(3):319–25. DOI: https://doi.org/10.1089/jpm.2018.0641 47. Ispol'zovanie kannabisa i kannabinoidov v medicinskih, nauchnyh i “rekreacionnyh” celjah: riski i pol'za. Tematicheskaja glava godovogo doklada Mezhdunarodnogo komiteta po kontrolju nad narkotikami OON (MKKN) za 2018 g. Voprosy narkologii. 2019;2(173):59–80. (In Russ.)
DOI: http://dx.doi.org/10.47877/1560-957Х-2021-10207
Article Metrics
Metrics powered by PLOS ALM